Trial Profile
A Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics, Pharmacodynamics Characteristics and Safety of Multiple Once-daily Oral Dosing of DPOC-4088 in Healthy Young Male Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs DP 4088 (Primary)
- Indications Blood coagulation disorders; Embolism and thrombosis
- Focus Pharmacokinetics
- Sponsors Diakron Pharmaceuticals
- 23 Feb 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 27 Jul 2012 New trial record